Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Increase in Short Interest
Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) saw a significant increase in short interest during the month of ...
Jane Street Group LLC Cuts Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC)
Jane Street Group LLC lowered its stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) by 77.6% during ...
Nature3y
Targeting oncology with two NK cell platforms
Working with a plug-and-play platform that can be applied to multiple therapeutic targets, Cytovia is advancing universal iPSC NK cells and iPSC CAR NK cells. A non-engineered universal candidate ...
EurekAlert!17d
Patient-derived induced pluripotent stem cell organoids for amyotrophic lateral sclerosis drug discovery
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
Nature3y
Engineered stem cells power expansive range of cancer therapies
Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...
Century Therapeutics launches cell therapy trial for autoimmune diseases
PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...
technologynetworks2mon
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating ... has allowed Dr. Fossati’s lab to identify and ...